Vaxart, Inc. (VXRT)
|Net Income (ttm)||-32.22M|
|Trading Day||March 1|
|Day's Range||7.08 - 7.64|
|52-Week Range||1.08 - 24.90|
VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume.
Vaxart stock (NASDAQ: VXRT) dropped -8% over the last five trading days and has underperformed the S&P 500 which remained roughly flat over the same period. The stock is also down by about -27...
The short answer: maybe.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather ...
Let's look at what short-sellers are saying and what science is saying.
In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.
VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
The choice isn't easy, but simplicity may be the answer.
The company can still produce returns without a COVID vaccine.
The short answer: Yes.
Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerat...
The once high-flying biotech stock has crashed.
The stock lost more than half its value in one trading session.
Hope for an oral COVID-19 vaccine remains alive.
This small-cap biotech just published clinical data for its experimental coronavirus vaccine, and investors are not happy.
Results from a phase 1 study show that the biotech's vaccine candidate, VXA-CoV2-1, falls short in one crucial area.
The biotech really needs some good news.
The coronavirus vaccine maker reported disappointing clinical trial results.
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Following short-squeeze hopes on Tuesday, Vaxart stock was down Wednesday on news of preliminary Phase I vaccine trial results. The post VXRT Stock: What To Know As Covid-19 Play Vaxart Plumme...
Vaxart stock crumbled Wednesday after the company said its coronavirus vaccine didn't generate detectable neutralizing antibodies in "most subjects." The post Vaxart Stock Crashes After Oral C...
The vaccine, which comes in the form of a small tablet, generated a type of T-cell responsible for destroying virus-infected cells in about 75% of volunteers.
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today annou...
Vaxart (VXRT) stock is heading higher Tuesday and there are a couple of things investors will want to keep in mind about the biotech company. The post VXRT Stock Alert: 2 Things for Vaxart Inv...
The GameStop short-squeeze saga has turned the spotlight on small and mid-cap stocks with a high level of short interest. Heavily shorted stocks could be targeted for so-called social trades b...
Probably not, if you're investing for the long term.
Two new breakout stocks for Week 5 of 2021 with better than 10% short-term upside potential. This past week all 4 stocks gained over 10% with NBSE and QDEL gaining over 20% before pulling back...
They can't vaccinate the whole world against COVID-19 -- but they may vaccinate all of the U.S.
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?
VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Investigation--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc. (NASDAQ: VX...
After the stock's magnificent run in 2020, it might be time to take profits.
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vaxart, Inc. (NASDAQ: VXRT) concerning the Company and its directors' and officers' possible viola...
Biotech company Vaxart's stock has rallied by about 40% over the last 5 trading days, with a bulk of the gains coming on Monday. The stock is also up by about 76% since the beginning of 2021, ...
Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rat...
New pre-clinical histology data show that Vaxart's oral vaccine protected against lung inflammation in hamster models
Biotech company Vaxart stock is up by over 11x through the last 12 months rising to levels of around $7 per share, driven by the company's efforts to develop a Covid-19 vaccine. Vaxart, which ...
No kidding around ... here's how they truly can.
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors t...
These companies' vaccines could bring in billions of dollars in revenue.
These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
There are some warning signs around this vaccine-maker that investors should take seriously.
Both of them already did it in 2020.
Can this small-cap biotech be part of the solution in the ongoing fight against COVID-19?
This high-flying biotech stock just might have more room to run. But it's risky.
Investors can start the new year off right by digging into these three small but fiery stocks.
The biotech stock could still have big gains ahead, and not just because of its COVID-19 vaccine candidate.
Did You Acquire (VXRT) Before June 25, 2020? Johnson Fistel Investigates Vaxart; Should Management be Held Accountable for Investors Losses?
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, investigates potential claims against Vaxart, Inc. (NASDAQ: VXRT) for violations of federal securities ...
Vaxart, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Vaxart's revenue was $4.05 million, a decrease of -58.97% compared to the previous year's $9.86 million. Losses were -$32.22 million, 72.8% more than in 2019.
According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 17.67, which is an increase of 134.04% from the latest price.